Aghamohammadi Asghar, Abolhassani Hassan, Kutukculer Necil, Wassilak Steve G, Pallansch Mark A, Kluglein Samantha, Quinn Jessica, Sutter Roland W, Wang Xiaochuan, Sanal Ozden, Latysheva Tatiana, Ikinciogullari Aydan, Bernatowska Ewa, Tuzankina Irina A, Costa-Carvalho Beatriz T, Franco Jose Luis, Somech Raz, Karakoc-Aydiner Elif, Singh Surjit, Bezrodnik Liliana, Espinosa-Rosales Francisco J, Shcherbina Anna, Lau Yu-Lung, Nonoyama Shigeaki, Modell Fred, Modell Vicki, Barbouche Mohamed-Ridha, McKinlay Mark A
Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Science, Tehran, Iran.
Faculty of Medicine, Department of Pediatric Immunology, Ege University, Izmir, Turkey.
Front Immunol. 2017 Jun 13;8:685. doi: 10.3389/fimmu.2017.00685. eCollection 2017.
Immunodeficiency-associated vaccine-derived polioviruses (iVDPVs) have been isolated from primary immunodeficiency (PID) patients exposed to oral poliovirus vaccine (OPV). Patients may excrete poliovirus strains for months or years; the excreted viruses are frequently highly divergent from the parental OPV and have been shown to be as neurovirulent as wild virus. Thus, these patients represent a potential reservoir for transmission of neurovirulent polioviruses in the post-eradication era. In support of WHO recommendations to better estimate the prevalence of poliovirus excreters among PIDs and characterize genetic evolution of these strains, 635 patients including 570 with primary antibody deficiencies and 65 combined immunodeficiencies were studied from 13 OPV-using countries. Two stool samples were collected over 4 days, tested for enterovirus, and the poliovirus positive samples were sequenced. Thirteen patients (2%) excreted polioviruses, most for less than 2 months following identification of infection. Five (0.8%) were classified as iVDPVs (only in combined immunodeficiencies and mostly poliovirus serotype 2). Non-polio enteroviruses were detected in 30 patients (4.7%). Patients with combined immunodeficiencies had increased risk of delayed poliovirus clearance compared to primary antibody deficiencies. Usually, iVDPV was detected in subjects with combined immunodeficiencies in a short period of time after OPV exposure, most for less than 6 months. Surveillance for poliovirus excretion among PID patients should be reinforced until polio eradication is certified and the use of OPV is stopped. Survival rates among PID patients are improving in lower and middle income countries, and iVDPV excreters are identified more frequently. Antivirals or enhanced immunotherapies presently in development represent the only potential means to manage the treatment of prolonged excreters and the risk they present to the polio endgame.
免疫缺陷相关的疫苗衍生脊髓灰质炎病毒(iVDPV)已从接触口服脊髓灰质炎疫苗(OPV)的原发性免疫缺陷(PID)患者中分离出来。患者可能会排出脊髓灰质炎病毒毒株数月或数年;排出的病毒通常与亲代OPV有很大差异,并且已证明其神经毒性与野生病毒一样强。因此,这些患者代表了根除后时代神经毒性脊髓灰质炎病毒传播的潜在储存库。为支持世界卫生组织关于更好地估计PID患者中脊髓灰质炎病毒排泄者的患病率并描述这些毒株的基因进化的建议,对来自13个使用OPV国家的635名患者进行了研究,其中包括570名原发性抗体缺陷患者和65名联合免疫缺陷患者。在4天内收集两份粪便样本,检测肠道病毒,并对脊髓灰质炎病毒阳性样本进行测序。13名患者(2%)排出了脊髓灰质炎病毒,大多数在感染确诊后不到2个月。5名(0.8%)被归类为iVDPV(仅在联合免疫缺陷患者中,且大多为脊髓灰质炎2型)。在30名患者(4.7%)中检测到非脊髓灰质炎肠道病毒。与原发性抗体缺陷患者相比,联合免疫缺陷患者脊髓灰质炎病毒清除延迟的风险增加。通常,在OPV暴露后的短时间内,联合免疫缺陷患者中检测到iVDPV,大多数不到6个月。在脊髓灰质炎根除得到认证且停止使用OPV之前,应加强对PID患者中脊髓灰质炎病毒排泄的监测。在低收入和中等收入国家,PID患者的生存率正在提高,iVDPV排泄者的发现更为频繁。目前正在研发的抗病毒药物或强化免疫疗法是管理长期排泄者治疗及其对脊髓灰质炎终结阶段所带来风险的唯一潜在手段。